Deep Track Capital has increased its stake in Structure Therapeutics (NASDAQ: GPCR) by acquiring 168,066 shares valued at approximately $11.50 million during the first quarter. Despite this addition, the total value of Deep Track’s holdings in Structure declined by $79.69 million, reflecting both the recent trading activity and fluctuations in share price. As of March 31, 2026, Deep Track’s position in Structure now represents 3.37% of its $6.12 billion in U.S. equity assets.
This move comes as Structure Therapeutics continues to gain traction, with its shares up 60% over the past year, significantly outperforming the S&P 500’s 28% rise. The company is advancing its oral GLP-1 candidate, aleniglipron, which has shown promising Phase 2 results for weight loss and is gearing up for Phase 3 studies. With a robust cash position of $1.5 billion, Structure is well-equipped to navigate upcoming trials and potential commercialization.
Investors should note that Deep Track’s confidence in Structure, despite its recent price surge, suggests that significant value-creating milestones may still lie ahead, particularly in the competitive obesity treatment market.
Source: nasdaq.com